Upgrade to SI Premium - Free Trial

RBC Capital on argenx SE (ARGX): 'We Are Buyers On Myositis Stock Weakness'

June 24, 2026 9:37 AM
RBC Capital analyst Luca Issi reiterated an Outperform rating and $890.00 price target on argenx ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

Analyst Comments